Diazepam buccal film - Aquestive Therapeutics

Drug Profile

Diazepam buccal film - Aquestive Therapeutics

Alternative Names: AQST-203; DBSF; Diazepam - Aquestive Therapeutics; Diazepam BSF; Diazepam buccal soluble film

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MonoSol Rx
  • Developer Aquestive Therapeutics
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • New Molecular Entity No

Highest Development Phases

  • Phase III Seizures
  • Phase II Epilepsy

Most Recent Events

  • 21 Apr 2018 Pharmacokinetics and adverse events data from a phase I trial in Seizure presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
  • 28 Mar 2018 Chemical structure information added
  • 23 Jan 2018 Phase-III clinical trials in Seizures (In children, In adolescents, In adults, In the elderly) in USA (Buccal) (NCT03428360)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top